CN110785486A - 肿瘤浸润淋巴细胞的生产方法及其在免疫治疗中的用途 - Google Patents

肿瘤浸润淋巴细胞的生产方法及其在免疫治疗中的用途 Download PDF

Info

Publication number
CN110785486A
CN110785486A CN201880035181.8A CN201880035181A CN110785486A CN 110785486 A CN110785486 A CN 110785486A CN 201880035181 A CN201880035181 A CN 201880035181A CN 110785486 A CN110785486 A CN 110785486A
Authority
CN
China
Prior art keywords
til
population
cells
days
tils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880035181.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·沃德尔
J·本德
M·T·洛策
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iovance Biotherapeutics Inc
Original Assignee
Iovance Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61569356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110785486(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iovance Biotherapeutics Inc filed Critical Iovance Biotherapeutics Inc
Publication of CN110785486A publication Critical patent/CN110785486A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201880035181.8A 2017-03-29 2018-01-05 肿瘤浸润淋巴细胞的生产方法及其在免疫治疗中的用途 Pending CN110785486A (zh)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201762478506P 2017-03-29 2017-03-29
US62/478,506 2017-03-29
US201762539410P 2017-07-31 2017-07-31
US62/539,410 2017-07-31
US201762548306P 2017-08-21 2017-08-21
US62/548,306 2017-08-21
US201762554538P 2017-09-05 2017-09-05
US62/554,538 2017-09-05
US201762559374P 2017-09-15 2017-09-15
US62/559,374 2017-09-15
US201762567121P 2017-10-02 2017-10-02
US62/567,121 2017-10-02
US201762577655P 2017-10-26 2017-10-26
US62/577,655 2017-10-26
US201762582874P 2017-11-07 2017-11-07
US62/582,874 2017-11-07
US201762596374P 2017-12-08 2017-12-08
US62/596,374 2017-12-08
PCT/US2018/012633 WO2018182817A1 (en) 2017-03-29 2018-01-05 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Publications (1)

Publication Number Publication Date
CN110785486A true CN110785486A (zh) 2020-02-11

Family

ID=61569356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880035181.8A Pending CN110785486A (zh) 2017-03-29 2018-01-05 肿瘤浸润淋巴细胞的生产方法及其在免疫治疗中的用途

Country Status (37)

Country Link
US (60) US10894063B2 (lt)
EP (6) EP3722415B1 (lt)
JP (6) JP7169291B2 (lt)
KR (2) KR102686794B1 (lt)
CN (1) CN110785486A (lt)
AU (2) AU2018243355B2 (lt)
BR (1) BR112019020326A2 (lt)
CA (1) CA3057975A1 (lt)
CL (2) CL2019002769A1 (lt)
CO (1) CO2019011995A2 (lt)
CR (1) CR20190487A (lt)
CY (1) CY1124136T1 (lt)
DK (3) DK3730608T3 (lt)
EC (1) ECSP19077884A (lt)
ES (3) ES3008832T3 (lt)
FI (2) FI3730608T3 (lt)
HR (3) HRP20210677T1 (lt)
HU (3) HUE070256T2 (lt)
IL (2) IL305198A (lt)
JO (1) JOP20190224A1 (lt)
LT (3) LT3601533T (lt)
MA (2) MA68856B1 (lt)
MD (3) MD3730608T2 (lt)
MX (2) MX2019011768A (lt)
NZ (2) NZ796142A (lt)
PE (1) PE20191841A1 (lt)
PH (1) PH12019502247A1 (lt)
PL (3) PL3601533T3 (lt)
PT (3) PT3722415T (lt)
RS (3) RS61863B1 (lt)
SG (1) SG11201908994RA (lt)
SI (3) SI3722415T1 (lt)
SM (3) SMT202500040T1 (lt)
TN (1) TN2019000273A1 (lt)
TW (1) TWI799402B (lt)
UA (1) UA130566C2 (lt)
WO (1) WO2018182817A1 (lt)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112513254A (zh) * 2018-03-29 2021-03-16 艾欧凡斯生物治疗公司 肿瘤浸润淋巴细胞的制备方法及其在免疫治疗中的用途
CN112969469A (zh) * 2018-11-05 2021-06-15 艾欧凡斯生物治疗公司 抗pd-1抗体难治性nsclc患者的治疗
WO2022111573A1 (zh) 2020-11-25 2022-06-02 上海君赛生物科技有限公司 增强细胞杀伤的药物组合物及其用途
WO2022111571A1 (zh) 2020-11-25 2022-06-02 上海君赛生物科技有限公司 肿瘤浸润淋巴细胞培养基及其应用
CN114686430A (zh) * 2020-12-31 2022-07-01 上海赛比曼生物科技有限公司 一种制备til的方法
CN115997008A (zh) * 2020-04-22 2023-04-21 艾欧凡斯生物治疗公司 协调用于患者特异性免疫疗法的细胞的制造的系统和方法

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013379773B2 (en) 2013-03-01 2018-04-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive T cells from peripheral blood
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
PL3532607T3 (pl) 2016-10-26 2024-07-01 Iovance Biotherapeutics, Inc. Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
JP7664020B2 (ja) 2017-01-06 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
US11254913B1 (en) * 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
WO2019103857A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
AR112072A1 (es) * 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
CN111601883B (zh) * 2017-11-17 2024-06-21 艾欧凡斯生物治疗公司 由细针抽吸物和小活检物扩增til
PH12020550661A1 (en) 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
KR102956273B1 (ko) 2018-01-08 2026-04-24 이오반스 바이오테라퓨틱스, 인크. 종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2019178420A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP3784254A1 (en) 2018-04-27 2021-03-03 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019217753A1 (en) * 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN113412259B (zh) 2018-10-15 2024-07-16 紐力克斯治疗公司 通过泛素蛋白酶体途径降解btk的双官能化合物
CR20210295A (es) 2018-11-05 2021-07-09 Iovance Biotherapeutics Inc Procesos para la producción de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
TW202039829A (zh) * 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 改善之腫瘤反應性ｔ細胞的選擇
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
CA3117895A1 (en) * 2018-11-08 2020-05-14 GammaDelta Therapeutics Limited Methods for isolating and expanding cells
WO2020131547A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
EP3908678A1 (en) 2019-01-10 2021-11-17 Iovance Biotherapeutics, Inc. System and methods for monitoring adoptive cell therapy clonality and persistence
WO2020167518A1 (en) 2019-02-13 2020-08-20 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
US20220257656A1 (en) * 2019-07-10 2022-08-18 National Cancer Center Specific marker for identifying t cells specifically attacking cancer cells
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
KR20220047258A (ko) * 2019-08-12 2022-04-15 벨리쿰 파마슈티컬스, 인크. 면역 세포에 대한 개선된 제제
AU2020334237B2 (en) 2019-08-19 2025-11-13 Universität Basel Cell therapy methods
US12121540B2 (en) * 2019-09-24 2024-10-22 Nurix Therapeutics, Inc. CBL inhibitors and compositions for use in adoptive cell therapy
WO2021081378A1 (en) * 2019-10-25 2021-04-29 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
MX2022006672A (es) 2019-12-04 2022-08-08 Nurix Therapeutics Inc Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina.
WO2021118990A1 (en) * 2019-12-11 2021-06-17 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
KR20220119439A (ko) 2019-12-20 2022-08-29 인스틸 바이오 유케이 리미티드 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine, Inc. Biased il2 muteins methods and compositions
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN115461062A (zh) 2020-04-28 2022-12-09 阿基里斯治疗英国有限公司 T细胞疗法
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
CN116018158A (zh) * 2020-04-30 2023-04-25 转化基因组学研究所 新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法
EP4146793A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
WO2021239083A1 (zh) * 2020-05-29 2021-12-02 上海君赛生物科技有限公司 肿瘤浸润淋巴细胞的种子细胞培养基及其应用
CN111876381A (zh) * 2020-07-22 2020-11-03 中美冠科生物技术（太仓）有限公司 一种t细胞模型及其在体外人源pd-1抗体药效评价中的应用
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
TW202237824A (zh) 2020-11-23 2022-10-01 美商萊爾免疫藥物股份有限公司 培養免疫細胞之方法
CA3201818A1 (en) 2020-12-11 2022-06-16 Maria Fardis Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
CA3202483A1 (en) * 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) * 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
JP2024500748A (ja) * 2020-12-18 2024-01-10 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球の処理
JP2023554425A (ja) * 2020-12-18 2023-12-27 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球の処理
EP4262828A1 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
CA3203382A1 (en) 2020-12-31 2022-07-07 Adrian Emanual Wells Devices and processes for automated production of tumor infiltrating lymphocytes
JPWO2022145490A1 (lt) * 2021-01-04 2022-07-07
WO2022165260A1 (en) * 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4288140A1 (en) * 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
WO2022182915A1 (en) 2021-02-25 2022-09-01 Lyell Immunopharma, Inc. Methods for culturing cells
CN117279506A (zh) 2021-03-05 2023-12-22 艾欧凡斯生物治疗公司 肿瘤储存及细胞培养组合物
JP2024510505A (ja) * 2021-03-19 2024-03-07 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｄ３９／ｃｄ６９選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張及びｔｉｌにおける遺伝子ノックアウトのための方法
WO2022204564A2 (en) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
JP2024512978A (ja) * 2021-03-30 2024-03-21 ネオジェント コーポレーション 免疫細胞組成物を生成するための方法
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
US20240210396A1 (en) 2021-04-09 2024-06-27 Achilles Therapeutics Uk Limited Batch release assay for pharmaceutical products relating to t cell therapies
KR20240037185A (ko) 2021-04-19 2024-03-21 이오반스 바이오테라퓨틱스, 인크. 키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도
AR125461A1 (es) 2021-04-27 2023-07-19 Takeda Pharmaceuticals Co Células presentadoras de antígeno recombinante
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
DE102021002748A1 (de) 2021-05-27 2022-12-01 Zellwerk Gmbh Verfahren zur Herstellung von Tumor-infiltrierten T-Lymphozyten (TIL) und deren Verwendung als Zell-Therapeutika für die Behandlung humaner Tumoren
AU2022292928A1 (en) * 2021-06-17 2024-01-25 CBio A/S Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use
AU2022299605A1 (en) 2021-06-22 2024-01-04 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells
JP2024526898A (ja) 2021-07-22 2024-07-19 アイオバンス バイオセラピューティクス，インコーポレイテッド 固形腫瘍断片の凍結保存のための方法
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
WO2023039488A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
CA3232700A1 (en) 2021-09-24 2023-03-30 Rafael CUBAS Expansion processes and agents for tumor infiltrating lymphocytes
WO2023076303A1 (en) 2021-10-26 2023-05-04 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3234821A1 (en) 2021-10-28 2023-05-04 Suman Kumar VODNALA Methods for culturing immune cells
US20250032618A1 (en) 2021-11-10 2025-01-30 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
US20250134999A1 (en) 2022-01-14 2025-05-01 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
CA3247927A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
US20250101380A1 (en) * 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
CA3247638A1 (en) 2022-04-06 2023-10-12 Maria Fardis TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA (NSCLC) WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES
WO2023201369A1 (en) * 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
US20250281537A1 (en) 2022-05-10 2025-09-11 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
GB202210006D0 (en) 2022-07-07 2022-08-24 Achilles Therapeutics Uk Ltd Analysis of T cell samples
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024055018A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
JP2025531877A (ja) 2022-09-09 2025-09-25 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１／ｔｉｇｉｔ ｔａｌｅｎダブルノックダウンを使用したｔｉｌ製品を生成するためのプロセス
US12181192B2 (en) * 2022-09-16 2024-12-31 Black & Decker, Inc. Methods and devices for controlling the temperature of a surface
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
EP4612277A1 (en) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024112711A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells
KR20250122544A (ko) 2022-11-21 2025-08-13 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
DE102023002417B3 (de) 2023-06-15 2024-12-05 Zellwerk Gmbh Verfahren zur Expansion von Zellen
WO2025006811A1 (en) 2023-06-27 2025-01-02 Lyell Immunopharma, Inc. Methods for culturing immune cells
EP4743565A2 (en) 2023-07-13 2026-05-20 Iovance Biotherapeutics Inc Lentiviral vectors encoding cytokines and their uses in the production of tumor-infiltrating lymphocytes
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025038289A1 (en) * 2023-08-17 2025-02-20 H. Lee Moffitt Cancer Center And Research Institute Inc. Using 12 chemokine signature to select sting agonist and til treatments for solid tumors
CN121773331A (zh) * 2023-08-31 2026-03-31 国立大学法人筑波大学 对肿瘤性滤泡调节性t细胞及肿瘤性滤泡杀伤性t细胞进行定量的方法、对肿瘤性滤泡调节性t细胞及肿瘤性滤泡杀伤性t细胞进行筛选的方法、治疗用组合物及试剂盒
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025256538A1 (zh) * 2024-06-12 2025-12-18 北京沙砾生物医药股份有限公司 一种细胞产品中检测肿瘤残留的方法
WO2026006604A1 (en) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Feeder cell replacement
CN118710478B (zh) * 2024-08-27 2025-01-03 福州大学 基于改进麻雀搜索算法的地铁突发运营中断客流疏运方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008099088A2 (fr) * 2007-01-12 2008-08-21 Centre Hospitalier Universitaire De Nantes Procede de culture in vitro de lymphocytes t, en particulier de lymphocytes t infiltrant les tumeurs dits til
US20120244133A1 (en) * 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2013057500A1 (en) * 2011-10-21 2013-04-25 Cell Medica Limited Device for the aseptic expansion of cells
WO2013088147A1 (en) * 2011-12-12 2013-06-20 Cell Medica Limited Process for t cell expansion
WO2015009604A1 (en) * 2013-07-15 2015-01-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing anti-human papillomavirus antigen t cells
US20150175966A1 (en) * 2009-12-08 2015-06-25 Juan F. Vera Methods of cell culture for adoptive cell therapy
WO2016053338A1 (en) * 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
CN106459917A (zh) * 2014-04-23 2017-02-22 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1988000970A2 (en) 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2000202A (en) 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040151704A1 (en) 2002-06-28 2004-08-05 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
ITMI20022118A1 (it) 2002-10-04 2004-04-05 Abiogen Pharma Spa Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo.
CN101120083B (zh) 2003-10-08 2013-03-27 威尔森沃尔夫制造公司 利用透气性材料进行细胞培养的方法及装置
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
AU2006328945B2 (en) 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
US8211425B2 (en) 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating disseminated cancer
US8007785B2 (en) 2005-12-21 2011-08-30 Sentoclone International Ab Method for treating colon cancer with tumour-reactive T-lymphocytes
AU2006328943B2 (en) 2005-12-21 2011-07-21 Sentoclone International Ab Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
US7951365B2 (en) 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
EP2203746B1 (en) * 2007-09-24 2013-03-06 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
US20150320798A1 (en) 2012-11-27 2015-11-12 The Johns Hopkins University Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
JP2013512694A (ja) 2009-12-08 2013-04-18 ウィルソン ウォルフ マニュファクチャリング コーポレイション 養子細胞療法のための細胞を培養する方法
KR102591732B1 (ko) 2010-11-12 2023-10-19 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
EP2697367B1 (en) 2011-04-13 2018-12-19 Immunicum AB Method for proliferation of antigen-specific t cells
CN102816734A (zh) 2012-05-09 2012-12-12 阮润生 一种肿瘤抗原特异性t细胞的获取方法
SG11201407226WA (en) 2012-05-18 2014-12-30 Wolf Wilson Mfg Corp Improved methods of cell culture for adoptive cell therapy
IL288241B2 (en) 2012-06-11 2023-10-01 Wilson Wolf Mfg Corporation Improved cell culture methods for stress cell therapy
DK2925329T3 (da) 2012-11-27 2021-03-22 Ivan Marques Borrello Anvendelse af cyclophosphamid-behandlede knoglemarvsinfiltrerende lymfocytter efter transplantationer til øgning af antitumorimmunitet
US20160010058A1 (en) 2013-03-01 2016-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of producing enriched populations of tumor-reactive t cells from tumor
AU2013379773B2 (en) 2013-03-01 2018-04-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive T cells from peripheral blood
SG10201705494YA (en) 2013-06-24 2017-08-30 Wolf Wilson Mfg Corp Closed system device and methods for gas permeable cell culture process
WO2015039100A1 (en) 2013-09-16 2015-03-19 The Trustees Of The University Of Pennsylvania Cd137 enrichment for efficient tumor infiltrating lymphocyte selection
MX374472B (es) 2014-03-20 2025-03-06 H Lee Moffitt Cancer Ct & Res Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
US20170044496A1 (en) 2014-04-10 2017-02-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
US20170107490A1 (en) 2014-06-11 2017-04-20 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
WO2015188839A2 (en) 2014-06-13 2015-12-17 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
US9687510B2 (en) 2014-09-04 2017-06-27 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
WO2016179006A1 (en) 2015-05-01 2016-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
FR3038324B1 (fr) 2015-06-30 2020-10-30 Lab Francais Du Fractionnement Procede de cryoconservation de cellules a visee therapeutique
FR3040396A1 (fr) 2015-06-30 2017-03-03 Chu Nantes Procede de cryoconservation de lymphocytes infiltrant la tumeur
WO2017048614A1 (en) 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood
US11466253B2 (en) 2015-10-22 2022-10-11 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
IL258935B2 (en) 2015-10-28 2024-08-01 Life Tech As Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio
KR20190037243A (ko) 2016-06-28 2019-04-05 지니우스 바이오테크놀로지 인코포레이티드 면역치료를 위한 티 세포 조성물
CN106244538A (zh) 2016-08-04 2016-12-21 英普乐孚生物技术(上海)有限公司 一种恶性腹水来源的til细胞的分离培养方法
HRP20201993T1 (hr) 2016-09-14 2021-02-05 Abbvie Biotherapeutics Inc. Protutijela protiv pd-1
PL3532607T3 (pl) 2016-10-26 2024-07-01 Iovance Biotherapeutics, Inc. Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
TWI826360B (zh) 2016-11-17 2023-12-21 美商艾歐凡斯生物治療公司 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
US20200095547A1 (en) 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
CN106591232A (zh) 2017-01-04 2017-04-26 安徽安龙基因医学检验所有限公司 一种高效的pd‑1‑cd8+t细胞的培养方法
JP7664020B2 (ja) 2017-01-06 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用
KR102903340B1 (ko) 2017-01-06 2025-12-26 이오반스 바이오테라퓨틱스, 인크. 종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
BR112019019005A2 (pt) 2017-03-14 2020-04-14 Sara Elizabeth Church métodos para armazenagem criogênica
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
MA50871A (fr) 2017-05-10 2020-03-18 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant des tumeurs à partir de tumeurs liquides et leurs utilisations thérapeutiques
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
CN107384867B (zh) 2017-08-04 2020-09-11 北京世纪劲得生物技术有限公司 一种肿瘤组织til细胞制备方法及专用培养基
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
JP2023524639A (ja) 2020-04-22 2023-06-13 アイオバンス バイオセラピューティクス，インコーポレイテッド 患者特異的免疫療法用細胞の製造調整システム及び調整方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008099088A2 (fr) * 2007-01-12 2008-08-21 Centre Hospitalier Universitaire De Nantes Procede de culture in vitro de lymphocytes t, en particulier de lymphocytes t infiltrant les tumeurs dits til
US20150175966A1 (en) * 2009-12-08 2015-06-25 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20120244133A1 (en) * 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2013057500A1 (en) * 2011-10-21 2013-04-25 Cell Medica Limited Device for the aseptic expansion of cells
WO2013088147A1 (en) * 2011-12-12 2013-06-20 Cell Medica Limited Process for t cell expansion
WO2015009604A1 (en) * 2013-07-15 2015-01-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing anti-human papillomavirus antigen t cells
CN106459917A (zh) * 2014-04-23 2017-02-22 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
WO2016053338A1 (en) * 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DONIA M等: "Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor", 《CYTOTHERAPY》 *
JIN J等: "Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment", 《J IMMUNOTHER》 *
MENG Q等: "Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)", 《PLOS ONE》 *
MENG Q等: "Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer", 《J IMMUNOTHER》 *
王永芬: "《动物细胞培养技术》", 31 July 2012 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112513254A (zh) * 2018-03-29 2021-03-16 艾欧凡斯生物治疗公司 肿瘤浸润淋巴细胞的制备方法及其在免疫治疗中的用途
CN112969469A (zh) * 2018-11-05 2021-06-15 艾欧凡斯生物治疗公司 抗pd-1抗体难治性nsclc患者的治疗
CN115997008A (zh) * 2020-04-22 2023-04-21 艾欧凡斯生物治疗公司 协调用于患者特异性免疫疗法的细胞的制造的系统和方法
WO2022111573A1 (zh) 2020-11-25 2022-06-02 上海君赛生物科技有限公司 增强细胞杀伤的药物组合物及其用途
WO2022111571A1 (zh) 2020-11-25 2022-06-02 上海君赛生物科技有限公司 肿瘤浸润淋巴细胞培养基及其应用
CN114686430A (zh) * 2020-12-31 2022-07-01 上海赛比曼生物科技有限公司 一种制备til的方法
WO2022143785A1 (en) * 2020-12-31 2022-07-07 Shanghai Cellular Biopharmaceutical Group Ltd. Methods for preparing tumor-infiltrating lymphocytes

Also Published As

Publication number Publication date
US10398734B2 (en) 2019-09-03
US20190000882A1 (en) 2019-01-03
JP7817138B2 (ja) 2026-02-18
US10463697B2 (en) 2019-11-05
US20200306306A1 (en) 2020-10-01
US11337998B2 (en) 2022-05-24
US20220008469A1 (en) 2022-01-13
US20200246384A1 (en) 2020-08-06
CA3057975A1 (en) 2018-10-04
US11517592B1 (en) 2022-12-06
US12226434B2 (en) 2025-02-18
US20210100843A1 (en) 2021-04-08
WO2018182817A1 (en) 2018-10-04
US11202803B1 (en) 2021-12-21
US20210361713A1 (en) 2021-11-25
MX2019011768A (es) 2019-12-09
MA68598B1 (fr) 2025-01-31
EP3730608B1 (en) 2024-10-23
PL3601533T3 (pl) 2021-08-16
US10905718B2 (en) 2021-02-02
US10894063B2 (en) 2021-01-19
JP2025023951A (ja) 2025-02-19
CL2019002769A1 (es) 2020-05-08
US20190083536A1 (en) 2019-03-21
US20200276241A1 (en) 2020-09-03
JP7772680B2 (ja) 2025-11-18
US11202804B2 (en) 2021-12-21
US11241456B2 (en) 2022-02-08
US11052116B2 (en) 2021-07-06
US20210207091A1 (en) 2021-07-08
AU2025200434A1 (en) 2025-02-20
NZ758201A (en) 2024-01-26
NZ796152A (en) 2026-03-27
PT3730608T (pt) 2025-01-07
JP2020515257A (ja) 2020-05-28
SMT202500027T1 (it) 2025-03-12
US20220362301A1 (en) 2022-11-17
SG11201908994RA (en) 2019-10-30
EP3722415B1 (en) 2024-11-06
US20200155601A1 (en) 2020-05-21
US20210207092A1 (en) 2021-07-08
US10953047B2 (en) 2021-03-23
JOP20190224A1 (ar) 2019-09-26
CY1124136T1 (el) 2022-05-27
US20230133298A1 (en) 2023-05-04
RS66452B1 (sr) 2025-02-28
SI3722415T1 (sl) 2025-03-31
MA68856B1 (fr) 2025-01-31
SI3730608T1 (sl) 2025-03-31
PT3722415T (pt) 2025-01-08
US11040070B2 (en) 2021-06-22
US20200276242A1 (en) 2020-09-03
US20230012086A1 (en) 2023-01-12
SMT202500040T1 (it) 2025-03-12
US11541077B2 (en) 2023-01-03
US11998568B2 (en) 2024-06-04
KR20240114787A (ko) 2024-07-24
US11168304B2 (en) 2021-11-09
RS66400B1 (sr) 2025-02-28
US20210353677A1 (en) 2021-11-18
US20190070222A1 (en) 2019-03-07
US11052115B2 (en) 2021-07-06
US20220378838A1 (en) 2022-12-01
US12611428B2 (en) 2026-04-28
IL269543A (en) 2019-11-28
US12622927B2 (en) 2026-05-12
TWI799402B (zh) 2023-04-21
US20210128621A1 (en) 2021-05-06
JP2021519582A (ja) 2021-08-12
HUE070256T2 (hu) 2025-05-28
US11007226B2 (en) 2021-05-18
US20190083538A1 (en) 2019-03-21
HRP20241688T1 (hr) 2025-02-14
US10272113B2 (en) 2019-04-30
MD3730608T2 (ro) 2025-03-31
US10695372B2 (en) 2020-06-30
US20220387495A1 (en) 2022-12-08
US20230015649A1 (en) 2023-01-19
DK3601533T3 (da) 2021-05-03
US20190000883A1 (en) 2019-01-03
US20190083539A1 (en) 2019-03-21
LT3730608T (lt) 2024-12-27
PT3601533T (pt) 2021-05-24
US10953046B2 (en) 2021-03-23
US20210379111A1 (en) 2021-12-09
MD3722415T2 (ro) 2025-05-31
US20190358259A1 (en) 2019-11-28
US20210214685A1 (en) 2021-07-15
US20190358260A1 (en) 2019-11-28
US10420799B2 (en) 2019-09-24
US20180325954A1 (en) 2018-11-15
US20220387499A1 (en) 2022-12-08
US20180282694A1 (en) 2018-10-04
RS61863B1 (sr) 2021-06-30
SI3601533T1 (sl) 2021-09-30
US11304979B2 (en) 2022-04-19
US10918666B2 (en) 2021-02-16
US20250121008A1 (en) 2025-04-17
US20180207201A1 (en) 2018-07-26
HUE070176T2 (hu) 2025-05-28
PH12019502247A1 (en) 2020-06-29
US12194061B2 (en) 2025-01-14
US11013770B1 (en) 2021-05-25
HRP20210677T1 (hr) 2021-06-25
US20250082683A1 (en) 2025-03-13
US12485145B2 (en) 2025-12-02
NZ796142A (en) 2026-01-30
TW201839129A (zh) 2018-11-01
UA130566C2 (uk) 2026-03-25
US20220387496A1 (en) 2022-12-08
CR20190487A (es) 2020-03-17
ECSP19077884A (es) 2020-01-31
US20210128623A1 (en) 2021-05-06
JP2023012511A (ja) 2023-01-25
CO2019011995A2 (es) 2020-02-18
EP3601533A1 (en) 2020-02-05
JP2023012510A (ja) 2023-01-25
US20220387494A1 (en) 2022-12-08
US10925900B2 (en) 2021-02-23
IL305198A (en) 2023-10-01
JP7814287B2 (ja) 2026-02-16
CL2020002737A1 (es) 2021-03-05
EP3766964A1 (en) 2021-01-20
BR112019020326A2 (pt) 2020-04-28
US10537595B2 (en) 2020-01-21
ES3009885T3 (en) 2025-03-31
US10639330B2 (en) 2020-05-05
US20200281978A1 (en) 2020-09-10
ES3008832T3 (en) 2025-03-25
EP3722415A1 (en) 2020-10-14
HUE054829T2 (hu) 2021-10-28
EP3910055A1 (en) 2021-11-17
US12558375B2 (en) 2026-02-24
LT3601533T (lt) 2021-06-10
US20230045899A1 (en) 2023-02-16
AU2018243355A1 (en) 2019-10-31
US10646517B2 (en) 2020-05-12
US20220000923A1 (en) 2022-01-06
JP7522037B2 (ja) 2024-07-24
US11529372B1 (en) 2022-12-20
JP7169291B2 (ja) 2022-11-10
US20220395533A1 (en) 2022-12-15
EP4279574A3 (en) 2024-04-10
US20190358261A1 (en) 2019-11-28
AU2018243355B2 (en) 2024-10-24
US20210128622A1 (en) 2021-05-06
US10946044B2 (en) 2021-03-16
US20210361712A1 (en) 2021-11-25
US10933094B2 (en) 2021-03-02
SMT202100298T1 (it) 2021-07-12
PL3730608T3 (pl) 2025-03-31
JP2023011778A (ja) 2023-01-24
EP4279574A2 (en) 2023-11-22
US20210079348A1 (en) 2021-03-18
US20250121009A1 (en) 2025-04-17
US10130659B2 (en) 2018-11-20
PL3722415T3 (pl) 2025-03-31
HRP20250068T1 (hr) 2025-03-14
US10946045B2 (en) 2021-03-16
KR102686794B1 (ko) 2024-07-24
LT3722415T (lt) 2025-01-10
US20210128620A1 (en) 2021-05-06
DK3730608T3 (da) 2024-12-16
US11273181B2 (en) 2022-03-15
TN2019000273A1 (en) 2021-01-07
US20220387498A1 (en) 2022-12-08
US20210100842A1 (en) 2021-04-08
FI3722415T3 (fi) 2025-01-10
DK3722415T3 (da) 2025-01-13
FI3730608T3 (fi) 2024-12-30
US20210106625A1 (en) 2021-04-15
US11007225B1 (en) 2021-05-18
US11083752B2 (en) 2021-08-10
PE20191841A1 (es) 2019-12-31
MX2024002827A (es) 2024-03-19
US20200289569A1 (en) 2020-09-17
US11344579B2 (en) 2022-05-31
US20200306307A1 (en) 2020-10-01
US20220387497A1 (en) 2022-12-08
MD3601533T2 (ro) 2021-07-31
US10363273B2 (en) 2019-07-30
US10166257B2 (en) 2019-01-01
US20220000924A1 (en) 2022-01-06
KR20190142342A (ko) 2019-12-26
US20210128625A1 (en) 2021-05-06
US20220000925A1 (en) 2022-01-06
US11291687B2 (en) 2022-04-05
ES2874335T3 (es) 2021-11-04
EP3601533B1 (en) 2021-02-24
US20210137984A1 (en) 2021-05-13
US11168303B2 (en) 2021-11-09
US11273180B2 (en) 2022-03-15
US12611429B2 (en) 2026-04-28
US12121541B2 (en) 2024-10-22
EP3730608A1 (en) 2020-10-28
US20210128624A1 (en) 2021-05-06
US20180280436A1 (en) 2018-10-04
US10653723B1 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
JP7814287B2 (ja) 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用方法
KR20250137200A (ko) 종양 침윤 림프구의 제조 방법 및 면역요법에서의 그의 용도
HK40021823A (en) Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40021823

Country of ref document: HK